Ultragenyx Pharmaceutical (RARE) Non-Current Assets (2013 - 2026)
Ultragenyx Pharmaceutical (RARE) posted quarterly Non-Current Assets of $639.0 million for Q1 2026, up 4.28% year-over-year from $612.8 million in Q1 2025, and up 9.98% quarter-over-quarter from $581.0 million in Q4 2025.
Ultragenyx Pharmaceutical (RARE) Non-Current Assets (2013 - 2026) Analysis & Trends
Ultragenyx Pharmaceutical (RARE) has reported Non-Current Assets for 14 consecutive years, with $639.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Non-Current Assets rose 4.28% year-over-year to $639.0 million; the TTM figure through Mar 2026 stood at $2.4 billion (down 12.54% YoY), while the FY2025 annual figure was $581.0 million, down 15.31% from the prior year.
- Non-Current Assets climbed to $639.0 million in Q1 2026 per RARE's latest filing, from $581.0 million in the prior quarter.
- Across five years, Non-Current Assets topped out at $758.8 million in Q4 2023 and bottomed at $547.2 million in Q3 2025.
- Historically, Non-Current Assets has averaged $645.1 million across 5 years, with a median of $639.0 million in 2026.
- Annual changes were most pronounced in 2022 — Non-Current Assets rose 28.41% — and 2025, when it dropped 25.92%.
- Ultragenyx Pharmaceutical's Non-Current Assets stood at $661.5 million in 2022, then climbed by 14.71% to $758.8 million in 2023, then decreased by 9.6% to $686.0 million in 2024, then slipped by 15.31% to $581.0 million in 2025, then increased by 9.98% to $639.0 million in 2026.
- Business Quant data shows RARE's Non-Current Assets at $639.0 million in Q1 2026, $581.0 million in Q4 2025, and $547.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.96 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 294.93 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.96 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 18.06 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 938.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 468.65 Mn |
| 10 | Ultragenyx Pharmaceutical | 2.61 Bn | 2.33 Bn | 180.00 Mn | 658.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 658.00 Mn |
| Mar 31, 2026 | 639.00 Mn |
| Dec 31, 2025 | 581.00 Mn |
| Sep 30, 2025 | 547.24 Mn |
| Jun 30, 2025 | 586.48 Mn |
| Mar 31, 2025 | 612.77 Mn |
| Dec 31, 2024 | 686.00 Mn |
| Sep 30, 2024 | 738.76 Mn |
| Jun 30, 2024 | 653.80 Mn |
| Mar 31, 2024 | 711.11 Mn |
| Dec 31, 2023 | 758.83 Mn |
| Sep 30, 2023 | 638.95 Mn |
| Jun 30, 2023 | 609.17 Mn |
| Mar 31, 2023 | 617.07 Mn |
| Dec 31, 2022 | 661.55 Mn |
| Sep 30, 2022 | 605.81 Mn |
| Jun 30, 2022 | 642.09 Mn |
| Mar 31, 2022 | 676.51 Mn |
| Dec 31, 2021 | 665.79 Mn |
| Sep 30, 2021 | 637.92 Mn |